


300436

2021096



2021

12 28

2021 542

1.

3CL

2021 12 24

3-CL 3C-like

3CL

PCC

NMPA

I

II


III

NMPA

NMPA

GMP

3CL

Paxlovid		FDA	1 2021 12 14 "Paxlovid" 89% "Paxlovid" " "	2021 12 22 FDA		1
		EUA	2 2021 12 22 PAXLOVID 89% 88% EPIC-HR EUA		3	

PF-073048

14

PF-0083

5231

Pfizer Inc.



Ib

			2 PBI-0451 I PBI-0451 PBI-0451 PBI-0451 3 180		
FB2001	/	I	1 FDA : 2021 4 28 2 FB2001		(688221.SH) 2021-031/047
SIM0417	/				02096.HK 2021 11 18

1 <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results> <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-receives-us-fda-emergency-use-authorization-novel>

2 <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-initiates-phase-1-study-novel-oral-antiviral>

Pfizer <https://clinicaltrials.gov/ct2/results?cond=&term=PF-07304814&cntry=&state=&city=&dist=>

3 https://www.shionogi.com/jp/ja/news/2021/10/211021_2.html

4 Pardes Bioscience <https://www.pardesbio.com/pipeline/> <https://ir.pardesbio.com/news-releases/news-release-details/pardes-biosciences-initiates-first-human-trial-forpbi-0451-oral>

3CL

Paxlovid

FDA

Medicines Patent Pool

MPP

<https://medicinespatentpool.org/news-publications-post/pfizer-and-the-medicines-patent-pool-mpp-sign-licensing-agreement-for-covid-19-oral-antiviral-treatment-candidate-to-expand-access-in-low-and-middle-income-countries>

MPP

95

/

PF-07321332

Paxlovid

95

/

I

3CL

3CL

1

3CL

2

3CL

3

2.

2

5%

3CL

2 —

2015

3CL

2021 12 23

3CL

“

	NMPA	NMPA
1		
3		
	2022	
4		3,400
5		
6		
1	PCC	
2		
3		
4		
7		
1		
2		

3

8

4.

3CL

3CL

1

2019

2

GMP

EHS

COO

CEO

GMP

3CL

3

5. 2021 2,053.19
236.76% -873.77

1

3CL

1 2021 2,053.19
-873.77

3CL

1

2 2021

3

3CL

III

3CL

2022

3,000

3,000

2

2021

2021

	2021		
	271,061,517.02	270,791,243.89	0.10%
	-20,531,919.56	15,012,979.21	-236.76%
	-28,633,147.34	4,791,607.54	-697.57%
	-8,737,728.68	10,588,502.12	-182.52%
/	-0.1404	0.1072	-230.93%
/	-0.1404	0.1072	-230.93%
	-2.80%	2.62%	-5.42%
	1,427,164,685.05	1,005,780,979.42	41.90%
	1,056,184,279.35	576,597,504.24	83.18%

2,053.19

236.76%

1

2019 9 2020 1

10.68%

16.81%

10.27%

3.45%

917.39

2

4,734.68

	2021			
	12,356.64	10,607.19	1,749.45	16.49%
	4,817.25	3,277.78	1,539.47	46.97%
	4,462.03	3,016.27	1,445.76	47.93%
	21,635.92	16,901.24	4,734.68	28.01%

1

1,749.45

2,200

1,300

450

2

1,539.47

700

500

3

4,462.03

1,445.76

47.93%

GST-HG161

GST-HG141

Ib

3

884.54

2,188.67

2021

346

3

2021

271,061,517.02

-20,531,919.56

-

A

2021 12 31

					12 24
603367		60.52	15.90	3.57%	4.21%
300194		60.91	25.60	21.33%	19.07%
000963		703.42	27.83	18.62%	10.93%
600196		1,254.28	26.39	-12.61%	-0.18%
600789		65.93	59.10	2.74%	6.09%
002653		219.64	59.88	8.11%	2.26%
688266		141.12	-36.16	-6.21%	0.51%
688321		143.79	-444.63	-2.48%	1.98%
300436		76.26	-278.57	51.32%	48.79%

12 24

48.79%

-278.57

12 24

60%

-277.81

1

项目	2021年7月9日	2022年1月10日
2		
3	18,777,000	
6		
6.	5%	
1		
5%		
2	2021年12月7日	
	13,614,866	
8.57%		3
6	3,175,540	
2%		
		5%

3